Greenway Reports 2025 Year In Review

Executive Summary

• Greenway reported a 20% increase in total revenue for 2025 and a >40% rise in average selling price per gram.
• The company completed build‑out of additional cultivation capacity (≈75% more production capability) and plans to bring it online without new capital expenditures.
• International wholesale expansion continued, highlighted by a strategic supply agreement with 4C Labs for the U.K. market.

Key Details

• Revenue Growth: 2025 total revenue up 20% year‑over‑year.
• Pricing Improvement: Average selling price per gram increased by >40%, driven by stronger demand and product quality.
• Cultivation Capacity: Additional greenhouse space built, raising potential production capacity by >75%; no incremental capex required to activate.
• International Expansion: Cannabis products sold in multiple European jurisdictions and Australia; new dedicated supply agreement with 4C Labs for U.K. medical market.
• Operational Efficiency: Refinements to crop scheduling, strain selection, and facility utilization yielded higher yields, tighter cost controls, and better production predictability across 2.5 acres of active cultivation.
• Share Issuance: On Dec 31 2025, issued 276,318 common shares at a deemed price of $0.19 per share from convertible debentures issued Oct 2023; subject to a 4‑month‑plus‑1‑day hold period, no change in control.
• Outlook: Management expects utilization of the new capacity to drive materially higher production volumes and top‑line growth in 2026 while preserving cost discipline.

Notable Quotes

“We delivered a 20% increase in total revenue during the calendar year, alongside an improvement in our average selling price per gram of over 40%, reflecting both stronger demand and the quality of our product.” – Jamie D'Alimonte, CEO

Materiality Assessment: Material – Positive (significant revenue and pricing improvements, capacity expansion, and international market development).